InsiderClue
← All stocks

Roivant Sciences Ltd.

ROIV Net selling
CIK 0001635088 #653 in the set updated 21 Sep 2026
Bought (12 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$912.32M
$9.46M on a plan · $405.65M straight out of an exercise
Sold at will
$497.21M
64 of 122 sales
Net
−$912.32M
−$497.21M against sales at will

By person

15 insiders · 122 transactions
929×

Matthew Gline holds 929 times base salary in stock. $673.89M of shares against $725.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Matthew Gline last reported holding, valued at $40.45, the price Common Shares was last bought or sold at on the open market here, on 15 Sep 2026.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
MANCHESTER KEITH S
Director
—
$154.47M (20)
−$154.47M
15,442,623
2.14%
$624.65M
−60.6%
Gold Daniel Allen
Director
—
$147.38M (19)
−$147.38M
22,654,981
3.14%
$916.39M
−67.4%
QVT Financial LP entity
Director by Deputization
—
$147.38M (19)
−$147.38M
13,689,166
1.90%
$553.73M
−76.0%
Sukhatme Mayukh
President & CIO
—
$109.13M (13) scheduled
−$109.13M
18,630,739
2.58%
$753.61M
−17.2%
Ramaswamy Vivek
10% owner
—
$105.88M (6) scheduled
−$105.88M
47,011,612
6.51%
$1.90B
−12.0%
Venker Eric
President & Immunovant CEO
—
$105.07M (25) scheduled
−$105.07M
1,599,154
0.2214%
$64.69M
+154.5%
Torti Frank
President and Vant Chair
—
$82.04M (3) scheduled
−$82.04M
13,536,202
1.87%
$547.54M
—
Gline Matthew
CEO
—
$46.17M (4) scheduled
−$46.17M
16,659,945
2.31%
$673.89M
−9.0%
Pulik Richard
CFO
—
$9.12M (2) scheduled
−$9.12M
271,810
0.0376%
$10.99M
−5.2%
Fitzgerald Meghan
Director
—
$3.27M (5) scheduled
−$3.27M
41,162
0.0057%
$1.67M
+40.1%
Epperly Melissa B,
Director
—
$2.01M (5)
−$2.01M
14,954
0.0021%
$604.89K
−58.9%
Humes Jennifer
Chief Accounting Officer
—
$384.07K (1)
−$384.07K
109,782
0.0152%
$4.44M
—
Kumar Rakhi
Chief Accounting Officer
—
—
—
162,306
0.0225%
$6.57M
−22.5%
Oren Ilan
Director
—
—
—
123,680
0.0171%
$5.00M
+29.4%
MOMTAZEE JAMES C
Director
—
—
—
111,959
0.0155%
$4.53M
+21.1%

Individual transactions

122
Insider
Date
Role
Action
Shares
Price
Amount
Fitzgerald Meghan
15 Sep 2026
Director
Sold on a plan
400
$40.45
$16.18K
Fitzgerald Meghan
15 Sep 2026
Director
Sold on a plan
4,712
$39.68
$186.97K
Epperly Melissa B,
15 Sep 2026
Director
Sold on a plan
600
$40.38
$24.23K
Epperly Melissa B,
15 Sep 2026
Director
Sold on a plan
4,338
$39.65
$172.00K
Fitzgerald Meghan
8 Sep 2026
Director
Sold after exercise
20,000
$39.90
$798.00K
Venker Eric
28 Aug 2026
President & Immunovant CEO
Sold after exercise
33,818
$36.44
$1.23M
Venker Eric
28 Aug 2026
President & Immunovant CEO
Sold after exercise
166,182
$35.63
$5.92M
Sukhatme Mayukh
21 Aug 2026
President & CIO
Sold after exercise
144,756
$36.48
$5.28M
Sukhatme Mayukh
20 Aug 2026
President & CIO
Sold after exercise
17,519
$37.30
$653.46K
Sukhatme Mayukh
19 Aug 2026
President & CIO
Sold after exercise
172,899
$37.17
$6.43M
Sukhatme Mayukh
18 Aug 2026
President & CIO
Sold after exercise
31,801
$37.18
$1.18M
Sukhatme Mayukh
18 Aug 2026
President & CIO
Sold after exercise
105,141
$36.59
$3.85M
Sukhatme Mayukh
17 Aug 2026
President & CIO
Sold after exercise
284,707
$36.25
$10.32M
Sukhatme Mayukh
14 Aug 2026
President & CIO
Sold after exercise
243,177
$36.23
$8.81M
Venker Eric
27 Jul 2026
President & Immunovant CEO
Sold after exercise
200,000
$34.95
$6.99M
QVT Financial LP
30 Jun 2026
Director by Deputization
Sell indirect
12,380
$35.28
$436.77K
Gold Daniel Allen
30 Jun 2026
Director
Sell indirect
12,380
$35.28
$436.77K
MANCHESTER KEITH S
30 Jun 2026
Director
Sell
200,000
$35.45
$7.09M
MANCHESTER KEITH S
30 Jun 2026
Director
Sell indirect
12,380
$35.28
$436.77K
Fitzgerald Meghan
30 Jun 2026
Director
Sold after exercise
10,000
$34.90
$349.00K
QVT Financial LP
29 Jun 2026
Director by Deputization
Sell indirect
600,000
$34.59
$20.75M
QVT Financial LP
29 Jun 2026
Director by Deputization
Sell indirect
200,000
$34.44
$6.89M
Gold Daniel Allen
29 Jun 2026
Director
Sell indirect
600,000
$34.59
$20.75M
Gold Daniel Allen
29 Jun 2026
Director
Sell indirect
200,000
$34.44
$6.89M
MANCHESTER KEITH S
29 Jun 2026
Director
Sell indirect
600,000
$34.59
$20.75M
MANCHESTER KEITH S
29 Jun 2026
Director
Sell indirect
200,000
$34.44
$6.89M
Epperly Melissa B,
29 Jun 2026
Director
Sold after exercise
2,748
$34.71
$95.38K
Epperly Melissa B,
29 Jun 2026
Director
Sold after exercise
15,002
$34.32
$514.87K
Sukhatme Mayukh
26 Jun 2026
President & CIO
Sold after exercise
500,000
$34.08
$17.04M
QVT Financial LP
26 Jun 2026
Director by Deputization
Sell indirect
325,000
$34.07
$11.07M
QVT Financial LP
26 Jun 2026
Director by Deputization
Sell indirect
300,783
$33.92
$10.20M
Gold Daniel Allen
26 Jun 2026
Director
Sell indirect
325,000
$34.07
$11.07M
Gold Daniel Allen
26 Jun 2026
Director
Sell indirect
300,783
$33.92
$10.20M
MANCHESTER KEITH S
26 Jun 2026
Director
Sell indirect
325,000
$34.07
$11.07M
MANCHESTER KEITH S
26 Jun 2026
Director
Sell indirect
300,783
$33.92
$10.20M
Sukhatme Mayukh
25 Jun 2026
President & CIO
Sold after exercise
500,000
$34.13
$17.07M
Venker Eric
24 Jun 2026
President & Immunovant CEO
Sold after exercise
46,234
$33.51
$1.55M
Venker Eric
24 Jun 2026
President & Immunovant CEO
Sold after exercise
153,766
$33.05
$5.08M
Venker Eric
22 May 2026
President & Immunovant CEO
Sold after exercise
200,000
$30.27
$6.05M
Venker Eric
20 Apr 2026
President & Immunovant CEO
Sold after exercise
200,000
$29.59
$5.92M
Gline Matthew
16 Apr 2026
CEO
Sell
289,774
$29.16
$8.45M
Humes Jennifer
8 Apr 2026
Chief Accounting Officer
Sell
13,538
$28.37
$384.07K
Fitzgerald Meghan
26 Mar 2026
Director
Sold after exercise
70,000
$27.45
$1.92M
Venker Eric
17 Mar 2026
President & Immunovant CEO
Sold after exercise
200,000
$28.24
$5.65M
Epperly Melissa B,
16 Mar 2026
Director
Sell
41,861
$28.68
$1.20M
Torti Frank
23 Feb 2026
President and Vant Chair
Sold after exercise
587,390
$27.51
$16.16M
Torti Frank
20 Feb 2026
President and Vant Chair
Sold after exercise
1,012,610
$27.15
$27.49M
Torti Frank
19 Feb 2026
President and Vant Chair
Sold after exercise
1,400,000
$27.42
$38.39M
QVT Financial LP
13 Feb 2026
Director by Deputization
Sell indirect
225,000
$26.50
$5.96M
QVT Financial LP
13 Feb 2026
Director by Deputization
Sell indirect
150,784
$26.49
$3.99M
Gold Daniel Allen
13 Feb 2026
Director
Sell indirect
225,000
$26.50
$5.96M
Gold Daniel Allen
13 Feb 2026
Director
Sell indirect
150,784
$26.49
$3.99M
MANCHESTER KEITH S
13 Feb 2026
Director
Sell indirect
225,000
$26.50
$5.96M
MANCHESTER KEITH S
13 Feb 2026
Director
Sell indirect
150,784
$26.49
$3.99M
Venker Eric
13 Feb 2026
President & Immunovant CEO
Sold after exercise
200,000
$26.49
$5.30M
QVT Financial LP
12 Feb 2026
Director by Deputization
Sell indirect
275,000
$26.76
$7.36M
QVT Financial LP
12 Feb 2026
Director by Deputization
Sell indirect
150,000
$26.72
$4.01M
Gold Daniel Allen
12 Feb 2026
Director
Sell indirect
275,000
$26.76
$7.36M
Gold Daniel Allen
12 Feb 2026
Director
Sell indirect
150,000
$26.72
$4.01M
MANCHESTER KEITH S
12 Feb 2026
Director
Sell indirect
275,000
$26.76
$7.36M
MANCHESTER KEITH S
12 Feb 2026
Director
Sell indirect
150,000
$26.72
$4.01M
QVT Financial LP
11 Feb 2026
Director by Deputization
Sell indirect
425,000
$26.67
$11.33M
Gold Daniel Allen
11 Feb 2026
Director
Sell indirect
425,000
$26.67
$11.33M
MANCHESTER KEITH S
11 Feb 2026
Director
Sell indirect
425,000
$26.67
$11.33M
Sukhatme Mayukh
9 Feb 2026
President & CIO
Sold after exercise
339,441
$26.47
$8.99M
Venker Eric
12 Jan 2026
President & Immunovant CEO
Sold after exercise
200,000
$21.92
$4.38M
Sukhatme Mayukh
31 Dec 2025
President & CIO
Sold after exercise
1,018,995
$21.71
$22.12M
Sukhatme Mayukh
29 Dec 2025
President & CIO
Sold after exercise
311,873
$21.74
$6.78M
Venker Eric
24 Dec 2025
President & Immunovant CEO
Sold after exercise
75,000
$22.53
$1.69M
Venker Eric
23 Dec 2025
President & Immunovant CEO
Sold after exercise
200,000
$22.45
$4.49M
Pulik Richard
23 Dec 2025
CFO
Sold after exercise
146,731
$22.39
$3.29M
Pulik Richard
23 Dec 2025
CFO
Sold after exercise
260,000
$22.45
$5.84M
QVT Financial LP
17 Dec 2025
Director by Deputization
Sell indirect
189,538
$23.17
$4.39M
QVT Financial LP
17 Dec 2025
Director by Deputization
Sell indirect
155,076
$23.02
$3.57M
QVT Financial LP
17 Dec 2025
Director by Deputization
Sell indirect
432,718
$23.05
$9.97M
MANCHESTER KEITH S
17 Dec 2025
Director
Sell indirect
189,538
$23.17
$4.39M
MANCHESTER KEITH S
17 Dec 2025
Director
Sell indirect
155,076
$23.02
$3.57M
MANCHESTER KEITH S
17 Dec 2025
Director
Sell indirect
432,718
$23.05
$9.97M
Gold Daniel Allen
17 Dec 2025
Director
Sell indirect
189,538
$23.17
$4.39M
Gold Daniel Allen
17 Dec 2025
Director
Sell indirect
155,076
$23.02
$3.57M
Gold Daniel Allen
17 Dec 2025
Director
Sell indirect
432,718
$23.05
$9.97M
Sukhatme Mayukh
17 Dec 2025
President & CIO
Sold after exercise
26,831
$23.09
$619.53K
QVT Financial LP
16 Dec 2025
Director by Deputization
Sell indirect
642,282
$23.08
$14.82M
QVT Financial LP
16 Dec 2025
Director by Deputization
Sell indirect
275,000
$22.93
$6.31M
MANCHESTER KEITH S
16 Dec 2025
Director
Sell indirect
642,282
$23.08
$14.82M
MANCHESTER KEITH S
16 Dec 2025
Director
Sell indirect
275,000
$22.93
$6.31M
Gold Daniel Allen
16 Dec 2025
Director
Sell indirect
642,282
$23.08
$14.82M
Gold Daniel Allen
16 Dec 2025
Director
Sell indirect
275,000
$22.93
$6.31M
Ramaswamy Vivek
15 Dec 2025
10% owner
Sold after exercise
353,745
$22.05
$7.80M
Gline Matthew
15 Dec 2025
CEO
Sold after exercise
943,527
$21.68
$20.46M
Gline Matthew
15 Dec 2025
CEO
Sold after exercise
566,116
$21.68
$12.27M
Gline Matthew
15 Dec 2025
CEO
Sold after exercise
230,357
$21.68
$4.99M
Ramaswamy Vivek
12 Dec 2025
10% owner
Sold after exercise
1,975,858
$21.96
$43.39M
Ramaswamy Vivek
11 Dec 2025
10% owner
Sold after exercise
774,142
$21.64
$16.75M
Venker Eric
9 Dec 2025
President & Immunovant CEO
Sold after exercise
200,000
$20.85
$4.17M
QVT Financial LP
19 Nov 2025
Director by Deputization
Sell indirect
175,000
$20.24
$3.54M
QVT Financial LP
19 Nov 2025
Director by Deputization
Sell indirect
125,000
$20.16
$2.52M
QVT Financial LP
19 Nov 2025
Director by Deputization
Sell indirect
150,000
$20.20
$3.03M
QVT Financial LP
19 Nov 2025
Director by Deputization
Sell indirect
850,000
$20.25
$17.21M
Gold Daniel Allen
19 Nov 2025
Director
Sell indirect
175,000
$20.24
$3.54M
Gold Daniel Allen
19 Nov 2025
Director
Sell indirect
125,000
$20.16
$2.52M
Gold Daniel Allen
19 Nov 2025
Director
Sell indirect
150,000
$20.20
$3.03M
Gold Daniel Allen
19 Nov 2025
Director
Sell indirect
850,000
$20.25
$17.21M
MANCHESTER KEITH S
19 Nov 2025
Director
Sell indirect
175,000
$20.24
$3.54M
MANCHESTER KEITH S
19 Nov 2025
Director
Sell indirect
125,000
$20.16
$2.52M
MANCHESTER KEITH S
19 Nov 2025
Director
Sell indirect
150,000
$20.20
$3.03M
MANCHESTER KEITH S
19 Nov 2025
Director
Sell indirect
850,000
$20.25
$17.21M
Ramaswamy Vivek
17 Nov 2025
10% owner
Sell
539,650
$20.51
$11.07M
Ramaswamy Vivek
14 Nov 2025
10% owner
Sell
1,027,670
$20.33
$20.89M
Ramaswamy Vivek
13 Nov 2025
10% owner
Sell
287,283
$20.81
$5.98M
Venker Eric
7 Nov 2025
President & Immunovant CEO
Sold after exercise
200,000
$20.22
$4.04M
Venker Eric
17 Oct 2025
President & Immunovant CEO
Sold after exercise
118,418
$17.06
$2.02M
Venker Eric
16 Oct 2025
President & Immunovant CEO
Sold after exercise
318,282
$17.05
$5.43M
Venker Eric
15 Oct 2025
President & Immunovant CEO
Sold after exercise
414,683
$16.93
$7.02M
Venker Eric
13 Oct 2025
President & Immunovant CEO
Sold after exercise
20,727
$16.25
$336.81K
Venker Eric
9 Oct 2025
President & Immunovant CEO
Sold after exercise
104,940
$16.30
$1.71M
Venker Eric
8 Oct 2025
President & Immunovant CEO
Sold after exercise
138,602
$16.20
$2.25M
Venker Eric
7 Oct 2025
President & Immunovant CEO
Sold after exercise
355,161
$16.15
$5.74M
Venker Eric
6 Oct 2025
President & Immunovant CEO
Sold after exercise
171,396
$16.34
$2.80M
Venker Eric
23 Sep 2025
President & Immunovant CEO
Sold on a plan
611,000
$14.83
$9.06M
Venker Eric
22 Sep 2025
President & Immunovant CEO
Sold after exercise
100,000
$15.01
$1.50M
Venker Eric
22 Sep 2025
President & Immunovant CEO
Sold after exercise
316,182
$14.99
$4.74M

What was left out

Form 4 filings counted 93
Amendments (4/A) skipped 0
Filings about a different issuer 1
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 5
Sales straight out of an exercise 53
Sales at will 64
Transactions with no price 0
Shares from compensation/vesting 35,449,297
History held since 17 Oct 2017